Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, 8635 West 3rd Street, 960-W Los Angeles, CA 90048, USA.
Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):110-7. doi: 10.1038/nrgastro.2009.218.
The treatment of patients with IBD has evolved towards biologic therapy, which seeks to target specific immune and biochemical abnormalities at the molecular and cellular level. Multiple genes have been associated with susceptibility to IBD, and many of these can be linked to alterations in immune pathways. These immune pathways provide avenues for understanding the pathogenesis of IBD and suggest future drug targets, such as the IL-12-IL-23 pathway. In addition, failed therapeutic drug trials can provide valuable information about pitfalls in study design, drug delivery and disease activity assessment. Future biologic drug development will benefit from the early identification of subsets of patients who are most likely to respond to therapy by use of biological markers of genetic susceptibility or immunologic susceptibility.
IBD 患者的治疗已经向生物治疗发展，旨在针对分子和细胞水平的特定免疫和生化异常。多个基因与 IBD 的易感性相关，其中许多基因可以与免疫途径的改变相关联。这些免疫途径为了解 IBD 的发病机制提供了途径，并提示了未来的药物靶点，例如 IL-12-IL-23 途径。此外，治疗药物试验的失败可以为研究设计、药物输送和疾病活动评估中的陷阱提供有价值的信息。通过使用遗传易感性或免疫易感性的生物标志物来早期识别最有可能对治疗有反应的患者亚群，将使未来的生物药物开发受益。
